These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23771499)

  • 21. The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
    Moon JY; Woo JS; Seo JW; Lee A; Kim DJ; Kim YG; Kim SY; Lee KH; Lim SJ; Cheng XW; Lee SH; Kim W
    PLoS One; 2016; 11(3):e0150745. PubMed ID: 26959365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.
    Seo JB; Choi YK; Woo HI; Jung YA; Lee S; Lee S; Park M; Lee IK; Jung GS; Park KG
    Diabetes Metab J; 2019 Dec; 43(6):830-839. PubMed ID: 30877711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
    Jung E; Kim J; Ho Kim S; Kim S; Cho MH
    Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
    Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
    Lee SW; Park SI; Lee S; Chung JY; Yu KS
    Int J Clin Pharmacol Ther; 2019 Feb; 57(2):117-124. PubMed ID: 30574864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
    Ahn CH; Kim EK; Min SH; Oh TJ; Cho YM
    Diabetes Obes Metab; 2017 Mar; 19(3):457-462. PubMed ID: 27868366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
    Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Toth PP
    Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
    Choi HY; Kim YH; Kim MJ; Lee SH; Bang K; Han S; Lim HS; Bae KS
    Drugs R D; 2014 Sep; 14(3):165-76. PubMed ID: 24962635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.
    Bae JC; Min KW; Kim YH; Kim KA; Hong EG; Park CY; Han S; Cha BS
    Diabetes Obes Metab; 2019 Jan; 21(1):103-111. PubMed ID: 30084112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin].
    Tsubamoto Y; Goto M
    Nihon Yakurigaku Zasshi; 2013 Jun; 141(6):339-49. PubMed ID: 23749075
    [No Abstract]   [Full Text] [Related]  

  • 35. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
    Park SE; Lee BW; Kim JH; Lee WJ; Cho JH; Jung CH; Lee SH; Suh S; Hur GC; Kim SH; Jang YH; Park CY;
    Diabetes Obes Metab; 2017 Jun; 19(6):892-896. PubMed ID: 28058753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
    Kwak SH; Hwang YC; Won JC; Bae JC; Kim HJ; Suh S; Lee EY; Lee S; Kim SY; Kim JH
    Diabetes Obes Metab; 2020 Feb; 22(2):173-181. PubMed ID: 31502749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 39. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
    Patel CG; Kornhauser D; Vachharajani N; Komoroski B; Brenner E; Handschuh del Corral M; Li L; Boulton DW
    Diabetes Obes Metab; 2011 Jul; 13(7):604-14. PubMed ID: 21332626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.